SCHEMBL6534161

SCHEMBL6534161

CCCCCCCCCCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)CC1OC(=O)CCCCCCCCCCCCCCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
SLC6A2 P23975 1/20 0.40
CACNA1F O60840 2/20 0.40
LMNA P02545 2/20 0.40
ALB P02768 2/20 0.40
MAPT P10636 2/20 0.40
CACNA1D Q01668 2/20 0.40
CACNA1S Q13698 2/20 0.40
CACNA1C Q13936 2/20 0.40
PDE3A Q14432 2/20 0.40
NLRP3 Q96P20 1/20 0.40
PRKCA P17252 5/20 0.39
P2RY2 P41231 1/20 0.39
P2RY4 P51582 1/20 0.39
P2RY6 Q15077 1/20 0.39
EP300 Q09472 1/20 0.39
POLG P54098 1/20 0.39
ABCG2 Q9UNQ0 3/20 0.38
ABCB1 P08183 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369313 0.89 POLB (0.56) POLBL3MBTL1CACNA1FLMNAALB
SCHEMBL2984540 0.89 POLB (0.56) POLBL3MBTL1CACNA1FLMNAALB
SCHEMBL5180509 0.88 POLB (0.46) POLBCACNA1FLMNAALBMAPT
SCHEMBL13036659 0.85 POLB (0.47) POLBL3MBTL1CACNA1FLMNAALB
SCHEMBL13036663 0.84 POLB (0.46) POLBL3MBTL1CACNA1FLMNAALB
SCHEMBL13036660 0.84 LMNA (0.45) POLBL3MBTL1CACNA1FLMNAALB
SCHEMBL3681067 0.82 LMNA (0.45) POLBL3MBTL1CACNA1FLMNAALB
SCHEMBL13894461 0.82 LMNA (0.45) POLBL3MBTL1CACNA1FLMNAALB
SCHEMBL9069652 0.82 L3MBTL1 (0.49) L3MBTL1LMNA
SCHEMBL10509769 0.81 L3MBTL1 (0.45) L3MBTL1CACNA1FLMNAALBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192635-A1 Acyl deoxyribonucleoside derivatives and uses thereof WELLSTAT THERAPEUTICS CORPORATION (US) 2004-09-30 US disclosed
US-6743782-B1 ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY WELLSTAT THERAPEUTICS CORPORATION 2004-06-01 US disclosed
US-6020320-A Acyl deoxyribonucleoside derivatives and uses thereof PRO-NEURON, INC. (US) 2000-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192635-A1 Acyl deoxyribonucleoside derivatives and uses thereof UNG, OGG1, NQO1 POLB 46/4885L3MBTL1 1306/4885SLC6A2 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.